Cullinan Oncology Inc expected to post a loss of 97 cents a share - Earnings Preview

Cullinan Therapeutics

04/08/2023 11:38

* Cullinan Oncology Inc  CGEM.OQ   CGEM.O  is expected
to show no
change in quarterly revenue when it reports  results on August 8
(estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Cullinan Oncology
Inc is
for a loss of 97 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Cullinan
Oncology
Inc is $24​, above​ its last closing price of $10.01. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -1.00       -0.98      -1.42     Missed  -44.9
 Dec. 31 2023  -0.63       -0.66      -0.59     Beat    11.3
 Sep. 30 2022  -0.95       -0.97      -0.54     Beat    44.1​
 Jun. 30 2022  5.42        5.42       3.77      Missed  -30.4
 ​​Mar.        -0.62       -0.61      -0.27     Beat    55.7
 31 2022                                                
 Dec. 31 2021              -0.47      -0.74     Missed  -56.3​
 Sep. 30 2021  -0.43       -0.42      -0.40     Beat    5.5
 Jun. 30 2021  -0.41       -0.41      -0.36     Beat    13.3
 This summary was machine generated August 4 at 10:38 GMT.  All
figures in US dollars  unless otherwise stated